InveniAI Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML), has entered a collaboration agreement with Kyowa Hakko Kirin to use AI and ML for drug discovery.    Through this collaboration, Kyowa Hakko Kirin, a life sciences company with a focus on new biologics and medicines for unmet medical needs, will leverage InveniAI’s platform – AlphaMeld™ – to maximize portfolio value through the re-innovation of an existing thera...